Dr. Lucia Seminario Vidal, MD, PhD

Dr. Seminario Vidal practices at Weinkle Dermatology, Inc. in Bradenton, Florida.

Dr. Seminario Vidal's NPI, 1588912869, was assigned on August 17, 2012. Dr. Seminario Vidal graduated from Cayetano Heredia University in 2004. Dr. Seminario Vidal holds Florida license ME127292.

Dr. Seminario Vidal's primary practice is Weinkle Dermatology, Inc., at 5601 21st W Ave, Bradenton, FL 34209 in Manatee County. The practice phone is (941) 794-5432.

Dr. Seminario Vidal's primary practice is Weinkle Dermatology, Inc. in Bradenton, Florida. The medical group on file is Weinkle Dermatology. Dmand AI also links Dr. Seminario Vidal to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Seminario Vidal practices. Vendor and product names are available with a free account.

Dermatology is Dr. Seminario Vidal's primary specialty in the NPI Registry, under taxonomy code 207N00000X. Dr. Seminario Vidal is board certified in dermatology by the American Board of Dermatology. Dmand AI has Dr. Seminario Vidal's licenses on file in 2 states: Florida and Alabama.

Dmand AI lists acute skin infection, benign or precancerous skin growths, contact dermatitis, itchy rashes, psoriasis, rash, skin cyst and skin discoloration among the conditions Dr. Seminario Vidal treats.

CMS data shows 38 Medicare services from Dr. Seminario Vidal across 2 procedure codes in 2024, all of them office visits, for 39 Medicare patients. Medicare paid $2,319 for them. Every service was in an office.

CMS counts 39 Medicare patients who saw Dr. Seminario Vidal in 2024. The largest group is 75 to 84, with 19 patients. 75% of them have high cholesterol, and 72% have high blood pressure. Their average risk score is 1.08, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Seminario Vidal's median patient age at 72, with 49% women.

In 2024, Dr. Seminario Vidal wrote 73 Medicare Part D claims for 24 patients. 97% of them were for generic drugs. CMS names the drug for 35 of them, across 2 drugs with 11 or more claims each, at $1,079 in total drug cost. In 2023, CMS named 23 claims across 2 drugs.

Dr. Seminario Vidal accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS counts 33 procedures of removal of skin lesions by Dr. Seminario Vidal, more than 69% of the clinicians it reports for that procedure.

Dmand AI links 4 papers to Dr. Seminario Vidal, published from 2019 to 2021. 2021 was the busiest year, with 2. Dr. Seminario Vidal's most frequent co-authors are Benjamin Harris Kaffenberger, MD, Alex G. Ortega Loayza, MD and Thomas Marshall Beachkofsky, MD.

Dmand AI links Dr. Seminario Vidal to 12 clinical trials, 6 of them phase 3 studies. Conditions studied include Lymphoma, T-Cell, Cutaneous, Pruritus and Dermatitis, Atopic. Novartis Pharmaceuticals sponsors the most, 3.

CMS Open Payments shows 101 general payments to Dr. Seminario Vidal from 16 drug and device companies from 2016 to 2021. Consulting fees make up the largest share, 46% of the total. Kyowa Kirin, Inc. paid the most, $32,241. It also lists 65 research payments totaling $70,471 from 2017 to 2022.

Dr. Seminario Vidal graduated from Cayetano Heredia University in 2004.

Dr. Seminario Vidal is in network with 10 carriers, including Elevance, Excellus BlueCross BlueShield and Blue Cross Blue Shield of Michigan. Medicare plans come from the most carriers, 9. Check the plan with the practice before a visit.